(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 March 2011 (10.03.2011)

PCT

(10) International Publication Number
WO 2011/028689 A1

(51) International Patent Classification:
A01N 43/40 (2006.01) *A61K 31/44* (2006.01)

(21) International Application Number:
PCT/US2010/047262

(22) International Filing Date:
31 August 2010 (31.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/238,903 1 September 2009 (01.09.2009) US
61/308,524 26 February 2010 (26.02.2010) US
61/310,952 5 March 2010 (05.03.2010) US

(71) Applicant *(for all designated States except US)*: **CATABASIS PHARMACEUTICALS, INC.** [US/US]; 161 First Street, Suite 1A, Cambridge, Massachusetts 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MILNE, Jill C.** [US/US]; 169 Mason Terrace, Brookline, Massachusetts 02446 (US). **JIROUSEK, Michael R.** [US/US]; 350 Third Street #2204, Cambridge, Massachusetts 02142 (US). **BEMIS, Jean E.** [US/US]; 256 Appleton Street, Arlington, Massachusetts 02476 (US). **VU, Chi B.** [US/US]; 79 Bay State Road, Arlington, Massachusetts 02474 (US).

(74) Agents: **TUSCAN, Michael S.** et al.; Cooley LLP, 777 6th St, NW, Suite 1100, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

WO 2011/028689 A1

(54) Title: FATTY ACID NIACIN CONJUGATES AND THEIR USES

(57) Abstract: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.